Cooley-Led Eliem Therapeutics Prices $80M IPO
Clinical-stage biotechnology company Eliem Therapeutics priced an $80 million initial public offering and began trading Tuesday, guided by Cooley LLP and underwriters' counsel Latham & Watkins LLP....To view the full article, register now.
Already a subscriber? Click here to view full article